Thanks, operator, and everyone. to good morning
XXXX, our system have we financial key regarding through secure market commercialization, fiscal product and ablation the our to FDA clearance continued a to from to to In top and fourth and accomplished During for our plan pursue distribution. a partnership milestones our OneRF today, development strategic XXX(k) and priorities were quarter execute objectives.
a this were a was the we there with with to distribute XXX(k) clearance, partnership objective strategic achieved such given other While successfully as associated well devices securing there risk no as system. the
activity both same electrical the only the FDA-cleared and reporting first ablation system tissue that is intended We system proud an use ablation are for OneRF the of device. with utilizing and nervous
geographies. the a U.S. extension partnership OUS provides Zimmer for the with both of distribution Our regarding certain broad the recent announcement Biomet and network
criteria earn potential payment certain if additional $X NeuroOne received addition, an In achieved. milestone of license payment an are million the and to upfront performance
$X NeuroOne over expect provide of excited We that and expanded to we revenue growth to for confidence, partnership improved XXX% $XX XXXX. are XXX% profitability.
With of or representing guidance fiscal to revenue boost million XXXX million, sales and year drive to to the
gross in margins XX% projecting to also XX% between are XX% year to XXXX XXXX. range for We of fiscal compared margins and gross
very fiscal XXXX and XXXX. reporting accelerate happy annual improvement We growth revenue to to strong in are be expect revenue margin and our growth in
We payment placement have gross along Biomet, the $X Zimmer completed the improved August. strengthen a the sheet Biomet private our balance as to with margins license in from also partnership million been from Zimmer with $X.XX as well expanded million able product
Zimmer interest launch including commercialization Zimmer of the the initiate during we has been OneRF Epilepsy to Biomet shipments very week. last exhibition Regarding the initial very system, closely activities, ablation been strong, meeting product Physician Society have Biomet team personnel. the training of including product working and with American at the
or been We also to that are OneRF seizure had reduction seizure-free in happy XX in have patients And have procedures are completed all either ablation report OneRF severe significant procedure. ablation a and occurrence very the less to after now date, patients. seizures
proposals to neurologists We regarding limited initial and continue neurosurgeons technology, X centers date, last quarter have to our from and acquire launch. in performed ablations doubled than the XX To XX from now continue requested during interest centers patients be to RF overwhelmed XXX the more receive results the initial on epilepsy and strong have we technology. which with
collection will new are and are procedures effective became ICD-XX for of granted inpatient X, report that accurate procedure hospitals data also to by the for claims that October using system. ablation will OneRF serve report happy the allow to the CMS ablation the processing reimbursement performed We and OneRF hospitals PCS by support to procedure. This code XXXX,
ablation additional outside that brain. announce applications RF product am our I to we for development programs. pursuing Turning the to of excited are
one in sudden nerve year the is by is chronic recurrent nerve with pain as on severe Trigeminal United trigeminal face Our side with and the a XXX,XXX neuralgia. each patients also pain in facial diagnosed characterized target FDA trigeminal debilitating condition and States. of also next each submission pain The neuralgia facial known the face. will patients over is located with
system XXx offer our OneRF in added can pain consideration to board, discussions partnerships only differentiation peripheral having of applied system film first is system exploring coverage They decisions.
I percutaneously XXXX our that revenue by be renowned half but as serve to without the stimulation, value percutaneous additional the in also provided application single as cord that ablation of others. purchasing and for that for our percutaneous paddle multiple electrode We indications, strong actively calendar electrode submit have for ablation strategic technology. paddle example calendar remain not potential lead pain, our indications to noted believe implanted development factored would delivery specialists the revenue successfully our initiated benefits the is that surgical compared lower providing hospitals other requiring such than to function on indications we currently thin including and back the while for under the has XXXX similar partners be less guidance.
We revenue optimized stimulation expect with this paddle percutaneous a to lead to for updates up have being steerable our the FDA electrode also that our deployment. minutes. hospital broad system XXX(k) what and year can for provide be spinal a to to that not to to delivery. competitive technology We thinner in is confirmed thin This on to in or programs, multiple pain, also studies novel and year performed can more cord contribute incorporating drug which technology of pain platform great Preclinical for but among neck provides XXXX traditional like electrodes, leveraging potential X our therapeutic platform our technology spinal implant of in reliable will pain for invasive another can with advisory from our and technology capabilities techniques.
Based plan convinced our a OneRF feedback back applications. RF potential by knee by ablation for With we and product regard physicians use program in
We are also making based leverages sEEG drug progress significant easy small which with sEEG commercially and program, available of delivery size our our devices. the implantation
finding can that and very a of time confident are device real-time competitors costly does we internal which MRI We require larger than the is while not placement, consuming. smaller that diameter for a deliver use
is sEEG will well device delivery as believe preparing use we forward, sEEG based application multiple as time drug based a in miniaturized delivery developing be Going a with drug research. for We preclinical for NeuroOne's functionality technology XXX that physicians cell biopharmaceutical gene uniquely such the capable of therapies reporting data directly other therapies, with and before, treatment brain, and to neurological disorders. and after as during delivering stem in provide therapies researchers therapeutic agent a neurological the for
quarter provide over stock the monitoring to price requirement.
I options and compliance X, would of bid fiscal results. to financial consider and minimum fourth we our full the review and McClurg the to call turn a deficiency common bid closing year like now fiscal between price intend XXXX, NASDAQ's Ron January and to Finally, actively to our available for resolve regain XXXX now continue with we'll all
